Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

Back

Katherine Payne

Katherine Payne

Professor
The Uiversity of Manchester
United Kingdom

Biography

Katherine was awarded a personal Chair in Health Economics at The University of Manchester in August 2010. Katherine is also a registered pharmacist. Between 1990 and 1993, she worked as a hospital pharmacist and has since maintained links with the pharmacy profession to understand the training needs in health economics, in general, and the evaluation of genomic technologies specifically. She has extensive experience working as an academic health economist with different clinical research groups (pharmacy, psychiatry, genetics). Five years ago, Katherine joined the newly established Health Sciences - Methodology Group, which allowed her to develop applied and methodological grants. In 2007, she was awarded an RCUK Academic Fellowship to focus on the evaluation and valuation of genomic technologies including genomic-based diagnostics and pharmacogenetic tests. Based in the Manchester Centre for Health Economics, established in August 2012, she is now leading a research group that focuses on the evaluation and valuation of genomic technologies and stratified medicine.

Research Interest

Katherine has over 20 years experience as an academic health economist and an international reputation for the economics of genetic technologies and services. Katherine has established a number of innovative research collaborations with genetic and other clinical colleagues. Ongoing and recent projects include: evaluation of information provision and models of informed consent in bloodspot newborn screening programmes; identifying and costing pathways of care for people with ataxia; building economic model to identify the most appropriate interval for breast cancer screening; preliminary economic evaluation of high-throughput whole genome sequencing technologies; towards HTA of whole genome sequencing; economic evaluation of risk stratified breast screening programmes; and various economic evaluations of examples of stratified medicines (funded by NIHR HTA; NIHR Research for Patient Benefit; NIHR Programme Grants for Applied Research; EU Framework Seven; Department of Health; MRC).